<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005273</url>
  </required_header>
  <id_info>
    <org_study_id>CA020-016</org_study_id>
    <secondary_id>2021-000039-29</secondary_id>
    <secondary_id>U1111-1263-4850</secondary_id>
    <nct_id>NCT05005273</nct_id>
  </id_info>
  <brief_title>A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Randomized Double-blind Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of BMS-986207 in&#xD;
      combination with nivolumab and ipilimumab as first-line treatment for participants with stage&#xD;
      IV non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) meeting protocol-defined dose-limiting toxicity (DLT) criteria</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events (TRAEs)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS based on RECIST v1.1 by BICR</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Parts 1 &amp; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS based on RECIST v1.1 by Investigator's assessment</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Parts 1 &amp; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on RECIST v1.1 by BICR</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Parts 1 &amp; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR based on RECIST v1.1 by Investigator's assessment</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Parts 1 &amp; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) based on RECIST v1.1 by BICR</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Parts 1 &amp; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR based on RECIST v1.1 by Investigator's assessment</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Parts 1 &amp; 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Parts 1 &amp; 2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2: Arm A</arm_group_label>
    <arm_group_label>Part 2: Arm B</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-963558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2: Arm A</arm_group_label>
    <arm_group_label>Part 2: Arm B</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS-734016</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986207</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2: Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2: Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic 1L Stage IV non-small cell lung cancer (NSCLC) of&#xD;
             squamous or nonsquamous histology&#xD;
&#xD;
          -  No prior systemic anti-cancer treatment given as primary therapy for advanced or&#xD;
             metastatic NSCLC&#xD;
&#xD;
          -  Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 20&#xD;
             unstained slides of tumor tissue obtained during screening or prior to enrollment&#xD;
&#xD;
          -  Life expectancy of at least 3 months at the time of first dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase&#xD;
             (ALK), or c-ros oncogene 1 (ROS-1) mutations which are sensitive to available targeted&#xD;
             inhibitor therapy. Participants with nonsquamous histology and unknown EGFR, ALK, or&#xD;
             ROS-1 status are also excluded&#xD;
&#xD;
          -  Participants with known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF) V600E&#xD;
             mutations that are sensitive to available targeted inhibitor therapy. Participants&#xD;
             with unknown or indeterminate BRAF mutation status are eligible.&#xD;
&#xD;
          -  Untreated central nervous system metastases&#xD;
&#xD;
          -  Leptomeningeal metastases (carcinomatous meningitis)&#xD;
&#xD;
          -  Concurrent malignancy requiring treatment&#xD;
&#xD;
          -  Active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Interstitial lung disease&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>BMS-986207</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Opdivo</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Yervoy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

